

11/353307

FILE 'CAPLUS' ENTERED AT 23:48:30 ON 29 OCT 2006
L4 8 S L3

FILE 'CAOLD' ENTERED AT 23:49:58 ON 29 OCT 2006

=> s 13
L5 0 L3

=> file reg
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.44 209.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -6.00

FILE 'REGISTRY' ENTERED AT 23:50:11 ON 29 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2006 HIGHEST RN 911422-45-2
DICTIONARY FILE UPDATES: 27 OCT 2006 HIGHEST RN 911422-45-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> save 13
ENTER NAME OR (END):ten502261/a
ANSWER SET L3 HAS BEEN SAVED AS 'TEN502261/A'

=> log h
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.44 210.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE 0.00 -6.00

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 23:50:50 ON 29 OCT 2006

10/502261

8 L2

=> d 13 8 bib abs hitstr

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:314909 CAPLUS
DN 136:325568
TI Preparation of 2-phenyl-4-piperazinylpiperidine-1-carboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders
IN Alvaro, Giuseppe; Di Fabio, Romano; Maragni, Paolo; Tampieri, Marsia; Tranquillini, Maria Elvira
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|----------|
| PI | WO 2002032867 | A1 | 20020425 | WO 2001-GB4580 | 20011012 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2425876 | AA | 20020425 | CA 2001-2425876 | 20011012 |
| | AU 2001095723 | A5 | 20020429 | AU 2001-95723 | 20011012 |
| | EP 1326832 | A1 | 20030716 | EP 2001-976453 | 20011012 |
| | EP 1326832 | B1 | 20041006 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| | BR 2001014637 | A | 20030930 | BR 2001-14637 | 20011012 |
| | JP 2004511544 | T2 | 20040415 | JP 2002-536051 | 20011012 |
| | AT 278669 | E | 20041015 | AT 2001-976453 | 20011012 |
| | PT 1326832 | T | 20050131 | PT 2001-976453 | 20011012 |
| | ES 2227287 | T3 | 20050401 | ES 2001-1976453 | 20011012 |
| | EP 1524266 | A1 | 20050420 | EP 2004-77714 | 20011012 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR | | | | |
| | NZ 525091 | A | 20050429 | NZ 2001-525091 | 20011012 |
| | NO 2003001561 | A | 20030614 | NO 2003-1561 | 20030407 |
| | ZA 2003002801 | A | 20040421 | ZA 2003-2801 | 20030410 |
| | US 2004014770 | A1 | 20040122 | US 2003-398264 | 20030729 |
| | US 7119092 | B2 | 20061010 | | |
| | HK 1058788 | A1 | 20050527 | HK 2004-100241 | 20040113 |
| | US 2005137208 | A1 | 20050623 | US 2004-994605 | 20041122 |
| | US 7060702 | B2 | 20060613 | | |
| | AU 2005204234 | A1 | 20050915 | AU 2005-204234 | 20050824 |
| | US 2006142302 | A1 | 20060629 | US 2006-358631 | 20060221 |
| PRAI | GB 2000-25354 | A | 20001017 | | |
| | EP 2001-976453 | A3 | 20011012 | | |
| | WO 2001-GB4580 | W | 20011012 | | |
| | US 2003-398264 | A1 | 20030729 | | |
| | US 2004-994605 | A1 | 20041122 | | |
| OS | MARPAT 136:325568 | | | | |


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [R = halo or alkyl; R1 = alkyl; R2 = H or alkyl; R3 = H or alkyl; R4 = CF₃; R5 = H, alkyl, or COR₆; R6 = (cyclo)alkyl or (di)alkylamino; m = 0-3; n = 1-3; and pharmaceutically acceptable salts and solvates thereof] were prepared as tachykinin antagonists. For example, reductive amination 2-(R)-(4-fluoro-2-methylphenyl)-4-oxopiperidine-1-carboxylic acid [1-(R)-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamide (preparation given) with 1-acetylpirperazine using sodium triacetoxyborohydride gave a mixture of diastereomers. 4-(R)-II and 4-(S)-II were separated by flash chromatog. and the latter converted to its HCl salt. In a neurokinin 1 (NK1) receptor binding affinity assay, 4-(S)-II•HCl displace [³H]-substance P from recombinant human NK1 receptors expressed in Chinese Hamster Ovary cell membranes with pK_iof 9.36. In addition, oral administration of 4-(S)-II•HCl to gerbils inhibited foot tapping induced by an NK1 agonist with ED₅₀ of 0.05 mg/kg. I are useful for the treatment of CNS disorders, pain, sleep disorders, cognitive disorders, substance abuse, allergic disorders, emesis, gastrointestinal disorders, and depressive states (no data).
- IT 414910-17-1P 414910-18-2P 414910-31-9P
 414910-41-1P, 2-(R)-(4-Fluoro-2-methylphenyl)-4-(R)-[(4-tert-butoxycarbonyl)piperazin-1-yl]piperidine-1-carboxylic acid
 N-[1-(R)-[3,5-bis-trifluoromethylphenyl]ethyl]-N-methylamide
 414910-42-2P, 2-(R)-(4-Fluoro-2-methylphenyl)-4-(S)-[(4-tert-butoxycarbonyl)piperazin-1-yl]piperidine-1-carboxylic acid
 N-[1-(R)-[3,5-bis-trifluoromethylphenyl]ethyl]-N-methylamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
- RN 414910-17-1 CAPLUS
 CN 1-Piperazinecarboxylic acid, 4-[(2R,4R)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-18-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2R,4S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-31-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-41-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2R,4R)-1-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-42-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2R,4S)-1-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 414910-26-2P, 4-(R)- (4-Acetyl piperazin-1-yl)-2-(R)- (4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)- (3,5-bis-trifluoromethylphenyl)ethyl]-N-methyl amide 414910-27-3P,
 4-(S)- (4-Acetyl piperazin-1-yl)-2-(R)- (4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)- (3,5-bis-trifluoromethylphenyl)ethyl]-N-methyl amide 414910-36-4P, 4-(R)- (4-Acetyl piperazin-1-yl)-2-(R)- (4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methyl amide 414910-37-5P,
 4-(S)- (4-Acetyl piperazin-1-yl)-2-(R)- (4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methyl amide 414910-39-7P, 2-(R)- (4-Fluoro-2-methylphenyl)-4-(R,S)- (4-methyl-1-piperazinyl)piperidine-1-carboxylic acid N-[1-(R)- (3,5-bis-trifluoromethylphenyl)ethyl]-N-methyl amide 414910-43-3P,
 2-(R)- (4-Fluoro-2-methylphenyl)-4-(S)-piperazin-1-ylpiperidine-1-carboxylic acid N-[1-(R)- (3,5-bis-trifluoromethylphenyl)ethyl]-N-methyl amide 414910-45-5P 414910-47-7P,
 4-(S)- (4-Cyclopropanoylpiperazin-1-yl)-2-(R)- (4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)- (3,5-bis-trifluoromethylphenyl)ethyl]-N-methyl amide 414910-50-2P,
 4-(S)- [4-(2-Methylpropanoyl)piperazin-1-yl]-2-(R)- (4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)- (3,5-bis-trifluoromethylphenyl)ethyl]-N-methyl amide 414910-53-5P
 414910-55-7P 414910-56-8P 414910-58-0P,
 4-(S)- (4-Acetyl piperazin-1-yl)-2-(R)- (4-fluorophenyl)piperidine-1-carboxylic acid N-[1-(R)- (3,5-bis-trifluoromethylphenyl)ethyl]-N-methyl amide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-26-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-27-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-36-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-37-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-39-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-43-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(1-piperazinyl)-, (2R,4S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 414910-45-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-47-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-50-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-53-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-55-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-56-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-(1-piperazinyl)-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-58-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry:




- IT 414910-28-4P, 4-(R)-{(4-Acetyl piperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 414910-29-5P, 4-(S)-{(4-Acetyl piperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 414910-30-8P, 4-(S)-{(4-Acetyl piperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide methanesulfonate
 414910-32-0P 414910-33-1P, 4-(S)-{(4-Acetyl piperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide p-toluenesulfonate 414910-34-2P, 4-(R)-{(4-Acetyl piperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methylamide hydrochloride
 414910-35-3P, 4-(S)-{(4-Acetyl piperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methylamide hydrochloride 414910-38-6P
 414910-40-0P, 2-(R)-{(4-Fluoro-2-methylphenyl)-4-(S)-(piperazin-1-yl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide monohydrochloride
 414910-44-4P 414910-46-6P, 4-(R)-{(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 414910-49-9P, 4-(R)-[4-(2-Methylpropanoyl)piperazin-1-yl]-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-51-3P
 414910-52-4P 414910-54-6P 414910-57-9P,
 4-(R)-{(4-Acetyl piperazin-1-yl)-2-(R)-(4-fluorophenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-59-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-28-4 CAPLUS

10/502261

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 414910-29-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 414910-30-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-


10/502261

bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-,
(2R,4S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 414910-27-3
CMF C30 H35 F7 N4 O2

Absolute stereochemistry.



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 414910-32-0 CAPLUS


CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)-, sulfate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 414910-27-3
CMF C30 H35 F7 N4 O2


Absolute stereochemistry.

10/502261



CM 2

CRN 7664-93-9
CMF H₂ O₄ S




RN 414910-33-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1


CRN 414910-27-3
CMF C₃₀ H₃₅ F₇ N₄ O₂

Absolute stereochemistry.




CM 2

CRN 104-15-4
CMF C7 H8 O3 S



RN 414910-34-2 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/502261

RN 414910-35-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-38-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, monohydrochloride, (2R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 414910-40-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(1-piperazinyl)-,

10/502261

monohydrochloride, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 414910-44-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, dihydrochloride, (2R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


●2 HCl

10/502261

RN 414910-46-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-48-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 414910-49-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-51-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

● HCl


RN 414910-52-4 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

10/502261

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 414910-54-6 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● HCl

RN 414910-57-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-N-methyl-, (2R,4R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-59-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-N-methyl-, monohydrochloride, (2R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



• HCl

10/502261

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT